Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

Inclusion Criteria:

• The participant must have been diagnosed with CGD based on the referring physician'sconfirmation that NADPH oxidase activity is ≤5% (i.e., the percentage ofdihydrorhodamine-positive [DHR+] cells is ≤5% by flow cytometry) OR based onconfirmed pathogenic mutation in a CGD associated gene (CYBB, CYBA, NCF1, NCF2,NCF4, or CYBC1).

• The participant or the participant's legally authorized guardian or representative (if applicable) must be capable of giving signed informed consent.

• The participant (with assistance from the participant's legally authorizedguardian/representative or primary caregiver, if applicable) must be capable ofcomplying with the requirements and restrictions listed in the protocol and informedconsent form (ICF).

Exclusion Criteria:

• The participant has undergone an allogeneic bone marrow transplant orinvestigational gene therapy.

• The participant is unable to comply with the sample collection procedure based oninvestigator judgment.